Butterfly’s GA tool within its point-of-care ultrasound (POCUS) system is intended for rollout in regions with socioeconomic barriers to obstetric imaging services.
Researchers from the Technion—Israel Institute of Technology, together with collaborators from leading medical centers in the United States and Europe, have developed an artificial intelligence (AI) model that predicts both the risk of breast cancer recurrence and the likelihood that a patient will benefit from chemotherapy.
The system uses AI to optimize the placement of Edwards’ mitral valve repair device.
Scientists at the University of Utah (the U) have developed a new “lab-on-a-chip” device that uses artificial intelligence to rapidly predict cancer cell sensitivity to targeted therapies for children with T-cell acute lymphoblastic leukemia (T-ALL), an aggressive and difficult-to-treat cancer.
Noah Labs Vox uses AI algorithms to detect worsening heart failure based on patients’ voice recordings.
A Penn Medicine–led team has developed a first-of-its-kind artificial intelligence system that interprets cardiac MRI scans with performance approaching expert clinicians.
An MIT-led team is designing artificial intelligence systems for medical diagnosis that are more collaborative and forthcoming about uncertainty.
Applying artificial intelligence techniques to cardiac ultrasound data may make it easier to identify patients with advanced heart failure, a new study has found. The study—led by investigators at Weill Cornell Medicine, Cornell Tech, Cornell Ann S. Bowers College of Computing and Information Science, Columbia University Vagelos College of Physicians and Surgeons and NewYork-Presbyterian—offers the prospect of better care for many thousands of patients who may be overlooked due to the difficulty of diagnosing their condition.
No matter the size or severity, wounds on human skin are difficult to monitor while they heal. Biopsies disrupt the wound site and are too invasive for routine, repeated monitoring, and most medical imaging devices that could do the job are large, expensive, and booked up with more pressing diagnostics. Clinicians typically resort to visual inspection or quick measurements of the wound’s size over time.
There is a promising new drug for the rare disease mastocytosis, which is associated with skin lesions, among other things. Researchers at the University of Basel have now been able to use artificial intelligence to quantitatively measure for the first time the extent to which it reduces skin lesions.